Sugi Predict

Sugi Predict / Compounds / SCHEMBL1472338

SCHEMBL1472338

SCHEMBL1472338

O=[N+]([O-])c1ccc(Oc2c(Cl)cc(S(=O)(=O)Nc3ncccn3)cc2Cl)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ THRA P10827 3/20 0.57
▸ CYP2C9 P11712 1/20 0.52
▸ KMT2A Q03164 5/20 0.51
▸ MEN1 O00255 4/20 0.51
▸ SCN9A Q15858 1/20 0.51
▸ CRHBP P24387 1/20 0.47
▸ CRHR2 Q13324 1/20 0.47
▸ SLC22A12 Q96S37 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ GAA P10253 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HPGD P15428 3/20 0.44
▸ PDE7A Q13946 1/20 0.44
▸ PKM P14618 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1472337 0.89 THRA (0.59) THRACYP2C9KMT2AMEN1CRHBP
SCHEMBL1472451 0.88 THRA (0.54) THRACYP2C9KMT2AMEN1CRHBP
SCHEMBL1472150 0.85 ALDH1A1 (0.56) THRACYP2C9KMT2AMEN1CRHBP
SCHEMBL1472031 0.84 NFKBIA (0.64) THRAKMT2AMEN1ALDH1A1MAPT
SCHEMBL1471692 0.83 CRHBP (0.60) THRACYP2C9KMT2AMEN1CRHBP
SCHEMBL1471249 0.83 ALPL (0.57) THRACYP2C9KMT2AMEN1SLC22A12
SCHEMBL1471494 0.83 CYP2C9 (0.54) THRACYP2C9KMT2AMEN1CRHBP
SCHEMBL1472097 0.83 THRA (0.49) THRACYP2C9KMT2AMEN1SCN9A
SCHEMBL1471229 0.82 CYP2C9 (0.53) THRACYP2C9KMT2AMEN1CRHBP
SCHEMBL1472242 0.82 THRA (0.58) THRACYP2C9KMT2AMEN1CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 — — US disclosed
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 — — US disclosed
US-7915293-B2 Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases RIGEL PHARMACEUTICALS, INC. (US) 2011-03-29 — — US disclosed
WO-2005007621-A2 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2005-01-27 — — WO disclosed
US-20050009871-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009871-A1 Ubiquitin ligase inhibitors NEDD4, STUB1, UBE3A THRA 4803/4885CYP2C9 3737/4885KMT2A 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.